	US 12,233,082 B2
	Compositions and methods for multi-use suppression and acquisition of viruses
Ben Alexander, Minneapolis, MN (US)
Filed by Ben Alexander, Minneapolis, MN (US)
Filed on Feb. 18, 2022, as Appl. No. 17/675,847.
Claims priority of provisional application 63/195,710, filed on Jun. 2, 2021.
Prior Publication US 2022/0387465 A1, Dec. 8, 2022
Int. Cl. A61K 31/7048 (2006.01); A61K 31/122 (2006.01); A61K 31/4725 (2006.01); A61K 31/513 (2006.01)

CPC A61K 31/7048 (2013.01) [A61K 31/122 (2013.01); A61K 31/4725 (2013.01); A61K 31/513 (2013.01)]

2 Claims

1. A pharmaceutical composition for inhibiting an HIV infection and suppressing a herpes infection in an HIV-seronegative HSV-seropositive subject,

consisting of (a) valacyclovir, tenofovir, and etoposide; (b) valacyclovir, tenofovir, and emodin; or (c) valacyclovir, tenofovir, and nelfinavir, and optionally at least one alcohol:

wherein the composition is used for inhibiting resistance mutations while obstructing replication at phases of the viral reproductive process.